| 词条 | Minoxidil |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 394534793 | IUPAC_name = 6-(1-Piperidinyl)pyrimidine-2,4-diamine 3-oxide[1] 6-(1-Piperidinyl)-2,4-pyrimidinediamine 3-oxide[2] 2,4-pyrimidinediamine,6-(1-piperidinyl)-, 3-oxide[3] | image = File:Minoxidil structure.svg | width = 150 | image2 = Minoxidil-from-xtal-3D-balls.png | width2 = 135 | tradename = Rogaine | Drugs.com = {{drugs.com|monograph|minoxidil}} | pregnancy_US = C | legal_UK = P | legal_UK_comment = (for topical use, otherwise POM. Cannot be prescribed on the NHS) | legal_US =OTC | legal_US_comment = Rx only for by mouth form | routes_of_administration = By mouth / topical | metabolism = Primarily hepatic | elimination_half-life = 4.2 h | excretion = renal | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 38304-91-5 | ATC_prefix = C02 | ATC_suffix = DC01 | ATC_supplemental = {{ATC|D11|AX01}} | PubChem = 4201 | IUPHAR_ligand = 4254 | DrugBank_Ref = {{drugbankcite|changed|drugbank}} | DrugBank = DB00350 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 10438564 | UNII_Ref = {{fdacite|changed|FDA}} | UNII = 5965120SH1 | KEGG_Ref = {{keggcite|changed|kegg}} | KEGG = D00418 | ChEBI_Ref = {{ebicite|changed|EBI}} | ChEBI = 6942 | ChEMBL_Ref = {{ebicite|changed|EBI}} | ChEMBL = 802 | PDB_ligand = MXD | C=9 | H=15 | N=5 | O=1 | molecular_weight = 209.251 g/mol | StdInChI_Ref = {{stdinchicite|changed|chemspider}} | StdInChI = 1S/C9H15N5O/c10-7-6-8(12-9(11)14(7)15)13-4-2-1-3-5-13/h6H,1-5,10H2,(H2,11,12) | StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} | StdInChIKey = ZFMITUMMTDLWHR-UHFFFAOYSA-N |melting_point = 248|alt = A space filling model of the molecule.|solubility = <1|SMILES = Nc1cc(nc(N)[n+]1[O-])N2CCCCC2}}Minoxidil is an antihypertensive vasodilator medication, available as a generic medication and over the counter for the treatment of androgenic alopecia, a form of hair loss, in people.[4] Medical usesMinoxidil, applied topically, is widely used for the treatment of hair loss. It is effective in helping promote hair growth in people with androgenic alopecia regardless of sex.[5] About 40% of men experience hair regrowth after 3–6 months.[5] Minoxidil must be used indefinitely for continued support of existing hair follicles and the maintenance of any experienced hair regrowth.[4] Its effect in people with alopecia areata is unclear.[6] Side effectsMinoxidil is generally well tolerated, but common side effects include burning or irritation of the eye, itching, redness or irritation at the treated area, and unwanted hair growth elsewhere on the body. Exacerbation of hair loss/alopecia has been reported.[7][8] Severe allergic reactions may include rash, hives, itching, difficulty breathing, tightness in the chest, swelling of the mouth, face, lips, or tongue, chest pain, dizziness, fainting, tachycardia, headache, sudden and unexplained weight gain, or swelling of the hands and feet.[9] Temporary hair loss is a common side effect of minoxidil treatment.[10] Manufacturers note that minoxidil-induced hair loss is a common side effect and describe the process as "shedding". Alcohol and propylene glycol present in some topical preparations may dry the scalp, resulting in dandruff and contact dermatitis.[11]Side effects of oral minoxidil may include swelling of the face and extremities, rapid and irregular heartbeat, lightheadedness, cardiac lesions, and focal necrosis of the papillary muscle and subendocardial areas of the left ventricle.[8] Cases of allergic reactions to minoxidil or the non-active ingredient propylene glycol, which is found in some topical minoxidil formulations, have been reported. Pseudoacromegaly is an extremely rare side effect reported with large doses of oral minoxidil.[12] Minoxidil may cause hirsutism, although it is exceedingly rare and reversible by discontinuation of the drug.[13] Mechanism of actionThe mechanism by which minoxidil promotes hair growth is not fully understood. Minoxidil is a potassium channel opener,[14] causing hyperpolarization of cell membranes. Theoretically, by widening blood vessels and opening potassium channels, it allows more oxygen, blood, and nutrients to the follicles. This may cause follicles in the telogen phase to shed, which are then replaced by thicker hairs in a new anagen phase. Minoxidil is a prodrug that is converted by sulfation via the sulfotransferase enzyme SULT1A1 to its active form, minoxidil sulfate. Several studies demonstrated that the activity of sulfotransferase in hair follicles predict minoxidil response in the treatment of hair loss.[15][16][17] Minoxidil is less effective when the area of hair loss is large. In addition, its effectiveness has largely been demonstrated in younger men who have experienced hair loss for less than 5 years. Minoxidil use is indicated for central (vertex) hair loss only.[18] Minoxidil is also a vasodilator.[19] Two clinical studies are being conducted in the US for a medical device that may allow patients to determine if they are likely to benefit from minoxidil therapy.[20] HistoryInitial applicationMinoxidil was developed in the late 1950s by the Upjohn Company (later became part of Pfizer) to treat ulcers. In trials using dogs, the compound did not cure ulcers, but proved to be a powerful vasodilator. Upjohn synthesized over 200 variations of the compound, including the one it developed in 1963 and named minoxidil.[24] These studies resulted in FDA approving minoxidil (with the trade name 'Loniten') in the form of oral tablets to treat high blood pressure in 1979.[21] Hair growthWhen Upjohn received permission from the FDA to test the new drug as medicine for hypertension they approached Charles A. Chidsey MD, Associate Professor of Medicine at the University of Colorado School of Medicine.[22] He conducted two studies,[23][24] the second study showing unexpected hair growth. Puzzled by this side-effect, Chidsey consulted Guinter Kahn and discussed the possibility of using minoxidil for treating hair loss. Kahn along with his colleague Paul J. Grant MD obtained a certain amount of the drug and conducted their own research, apparently without notifying Upjohn or Chidsey.[25] The two doctors had been experimenting with a 1% solution of minoxidil mixed with several alcohol-based liquids.[26] They tried to patent the drug for hair loss prevention, but found that Upjohn had already done this. A decade-long trial between Kahn and Upjohn ended with Kahn's name included in a consolidated patent (U.S. #4,596,812 Charles A Chidsey, III and Guinter Kahn) in 1986 and royalties from the company to both Kahn and Grant.[25] Meanwhile the effect of minoxidil on hair loss prevention was so clear that in the 1980s physicians were prescribing Loniten off-label to their balding patients.[21] In August 1988, the FDA finally approved the drug for treating baldness in men[21][26] under the trade name "Rogaine" (FDA rejected Upjohn's first choice, Regain, as misleading[27]). The agency concluded that although "the product will not work for everyone", 39% of the men studied had "moderate to dense hair growth on the crown of the head".[27] In 1991, Upjohn made the product available for women.[26] On February 12, 1996, the FDA approved both the over-the-counter sale of the drug and the production of generic formulations of minoxidil.[21] Upjohn replied to that by lowering prices to half the price of the prescription drug[26] and by releasing a prescription 5% formula of Rogaine in 1997.[21] In 1998, a 5% formulation of minoxidil was approved for nonprescription sale by the FDA.[28] {{As of|2014}}, it was the only topical product that is FDA-approved for androgenic hair loss.[29]The drug is available over the counter in many countries, including United Kingdom,[4] (topical only) United States, (topical only) Sweden and Germany (available from registered pharmacies only). Trade names{{As of|June 2017}}, Minoxidil was marketed under many trade names worldwide: Alomax, Alopek, Alopexy, Alorexyl, Alostil, Aloxid, Aloxidil, Anagen, Apo-Gain, Axelan, Belohair, Boots Hair Loss Treatment, Botafex, Capillus, Carexidil, Coverit, Da Fei Xin, Dilaine, Dinaxcinco, Dinaxil, Ebersedin, Eminox, Folcare, Guayaten, Hair Grow, Hair-Treat, Hairgain, Hairgaine, Hairgrow, Hairway, Headway, Inoxi, Ivix, Keranique, Lacovin, Locemix, Loniten, Lonnoten, Lonolox, Lonoten, Loxon, M E Medic, Maev-Medic, Mandi, Manoxidil, Mantai, Men's Rogaine, Minodil, Minodril, Minostyl, Minovital, Minox, Minoxi, Minoxidil, Minoxidilum, Minoximen, Minoxiten, Minscalp, Mintop, Modil, Moxidil, Neo-Pruristam, Neocapil, Neoxidil, Nherea, Noxidil, Oxofenil, Pilfud, Pilogro, Pilomin, Piloxidil, Recrea, Regain, Regaine, Regaxidil, Regro, Regroe, Regrou, Regrowth, Relive, Renobell Locion, Reten, Rexidil, Rogaine, Rogan, Si Bi Shen, Splendora, Superminox, Trefostil, Tricolocion, Tricoplus, Tricovivax, Tricoxane, Trugain, Tugain, Unipexil, Vaxdil, Vius, Womens Regaine, Xenogrow, Xue Rui, Ylox, and Zeldilon.[30] It was also marketed as combination drug with amifampridine under the brand names Gainehair and Hair 4 U, and as a combination with tretinoin and clobetasol under the brand name Sistema GB.[30]See also
References1. ^{{cite web|last1=product|first1=sigma|title=M4145 Sigma ≥99% (TLC)|url=http://www.sigmaaldrich.com/catalog/product/sigma/m4145?lang=en®ion=US|website=sigmaaldrich.com|publisher=sigma|accessdate=29 September 2016|deadurl=no|archiveurl=https://web.archive.org/web/20161002141725/http://www.sigmaaldrich.com/catalog/product/sigma/m4145?lang=en®ion=US|archivedate=2 October 2016|df=}} 2. ^{{cite web|last1=cayman chemical|first1=company|title=safety data sheet|url=https://www.caymanchem.com/msdss/15302m.pdf|website=caymanchem.com|publisher=cayman chemical company|accessdate=29 September 2016|deadurl=no|archiveurl=https://web.archive.org/web/20161001215220/https://www.caymanchem.com/msdss/15302m.pdf|archivedate=1 October 2016|df=}} 3. ^{{cite web|last1=archives|first1=dailymed|title=loniten- minoxidil tablet|url=https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=166610|website=dailymed.nlm.nih.gov|publisher=dailymed|accessdate=29 September 2016|deadurl=no|archiveurl=https://web.archive.org/web/20160816072805/https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=166610|archivedate=16 August 2016|df=}} 4. ^1 2 {{cite web|title=Minoxidil Regular Strength|url=https://www.medicines.org.uk/emc/medicine/22865|publisher=UK Electronic Medicines Compendium|accessdate=8 January 2017|date=18 August 2015|deadurl=no|archiveurl=https://web.archive.org/web/20170108191632/https://www.medicines.org.uk/emc/medicine/22865|archivedate=8 January 2017|df=}} 5. ^{{cite journal | pmid = 25112173 | doi=10.1111/dth.12164 | volume=28 | issue=1 | title=Clinical utility and validity of minoxidil response testing in androgenetic alopecia | journal=Dermatologic Therapy | pages=13–6| year=2015 | author1=Goren | first1=A | last2=Shapiro | first2=J | last3=Roberts | first3=J | last4=McCoy | first4=J | last5=Desai | first5=N | last6=Zarrab | first6=Z | last7=Pietrzak | first7=A | last8=Lotti | first8=T }} 6. ^{{cite journal|last1=Hordinsky|first1=M|last2=Donati|first2=A|title=Alopecia areata: an evidence-based treatment update.|journal=American Journal of Clinical Dermatology|date=July 2014|volume=15|issue=3|pages=231–46|pmid=25000998|doi=10.1007/s40257-014-0086-4}} 7. ^{{cite web|url=https://www.drugs.com/sfx/rogaine-side-effects.html|title=Rogaine Side Effects in Detail - Drugs.com|author=|date=|website=drugs.com|deadurl=no|archiveurl=https://web.archive.org/web/20170922052041/https://www.drugs.com/sfx/rogaine-side-effects.html|archivedate=2017-09-22|df=}} 8. ^1 {{cite web | url = https://www.drugs.com/pro/minoxidil.html | title = Minoxidil Official FDA information, side effects and uses | publisher = Drugs.com | deadurl = no | archiveurl = https://web.archive.org/web/20170922051930/https://www.drugs.com/pro/minoxidil.html | archivedate = 2017-09-22 | df = }} 9. ^{{cite web|url=https://www.drugs.com/sfx/rogaine-side-effects.html|title=Rogaine Side Effects in Detail - Drugs.com|author=|date=|website=drugs.com|deadurl=no|archiveurl=https://web.archive.org/web/20170922052041/https://www.drugs.com/sfx/rogaine-side-effects.html|archivedate=2017-09-22|df=}} 10. ^{{cite web|url=http://www.rogaine.com/men/faq#question-9|title=FAQs for Men - Hair Growth Education - ROGAINE®|author=|date=|website=www.rogaine.com|deadurl=no|archiveurl=https://web.archive.org/web/20091110021804/http://www.rogaine.com/men/faq#question-9|archivedate=2009-11-10|df=}} 11. ^{{cite web | url = http://www.medscape.com/viewarticle/407641 | title = Dandruff and Seborrheic Dermatitis | accessdate = 2009-10-09 | publisher = Medscape.com | deadurl = no | archiveurl = https://web.archive.org/web/20101028074627/http://www.medscape.com/viewarticle/407641 | archivedate = 2010-10-28 | df = }} 12. ^{{cite journal | last1 = Nguyen | first1 = K. | last2 = Marks Jr | first2 = J. | title = Pseudoacromegaly induced by the long-term use of minoxidil | journal = Journal of the American Academy of Dermatology | volume = 48 | issue = 6 | pages = 962–965 | year = 2003 | pmid = 12789195 | doi = 10.1067/mjd.2003.325 }} 13. ^{{cite journal|last1=Dawber|first1=RP|last2=Rundegren|first2=J|title=Hypertrichosis in females applying minoxidil topical solution and in normal controls.|journal=Journal of the European Academy of Dermatology and Venereology |date=May 2003|volume=17|issue=3|pages=271–5|pmid=12702063|doi=10.1046/j.1468-3083.2003.00621.x}} 14. ^{{Cite journal | pmid = 12538840| year = 2003| last1 = Wang| first1 = T.| title = The effects of the potassium channel opener minoxidil on renal electrolytes transport in the loop of henle| journal = The Journal of Pharmacology and Experimental Therapeutics| volume = 304| issue = 2| pages = 833–40| doi = 10.1124/jpet.102.043380}} 15. ^{{Cite journal | doi = 10.1111/dth.12164| title = Clinical utility and validity of minoxidil response testing in androgenetic alopecia| journal = Dermatologic Therapy| volume = 28| issue = 1| pages = 13–6| year = 2015| last1 = Goren | first1 = A. | last2 = Shapiro | first2 = J. | last3 = Roberts | first3 = J. | last4 = McCoy | first4 = J. | last5 = Desai | first5 = N. | last6 = Zarrab | first6 = Z. | last7 = Pietrzak | first7 = A. | last8 = Lotti | first8 = T. | pmid=25112173}} 16. ^{{Cite journal | doi = 10.1111/dth.12130| pmid = 24773771| title = Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil in the treatment of female androgenetic alopecia| journal = Dermatologic Therapy| volume = 27| issue = 4| pages = 252–254| year = 2014| last1 = Roberts | first1 = J. | last2 = Desai | first2 = N. | last3 = McCoy | first3 = J. | last4 = Goren | first4 = A. }} 17. ^{{Cite journal | doi = 10.1111/dth.12111| pmid = 24283387| title = Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia| journal = Dermatologic Therapy| volume = 27| issue = 3| pages = 171–173| year = 2014| last1 = Goren | first1 = A. | last2 = Castano | first2 = J. A. | last3 = McCoy | first3 = J. | last4 = Bermudez | first4 = F. | last5 = Lotti | first5 = T. }} 18. ^{{cite journal |last1=Scow |first1=DT |last2=Nolte |first2=RS |last3=Shaughnessy |first3=AF |title=Medical treatments for balding in men |journal=American Family Physician |volume=59 |issue=8 |pages=2189–94 |date=April 1999 |pmid=10221304 |doi= |url=http://www.aafp.org/afp/1999/0415/p2189.html |deadurl=no |archiveurl=https://web.archive.org/web/20120928063613/http://www.aafp.org/afp/1999/0415/p2189.html |archivedate=2012-09-28 |df= }} 19. ^{{cite web|url=http://www.mayoclinic.com/health/high-blood-pressure-medication/HI00057|title=Vasodilators|author=|date=|website=mayoclinic.com|deadurl=no|archiveurl=https://web.archive.org/web/20110309092157/http://www.mayoclinic.com/health/high-blood-pressure-medication/hi00057|archivedate=2011-03-09|df=}} 20. ^{{cite web|url=http://clinicaltrials.gov/ct2/show/NCT02198261?term=minoxidil&rank=1|title=Minoxidil Response Testing in Males With Androgenetic Alopecia - Full Text View - ClinicalTrials.gov|author=|date=|website=clinicaltrials.gov|deadurl=no|archiveurl=http://archive.wikiwix.com/cache/20170118154857/http://clinicaltrials.gov/ct2/show/NCT02198261?term=minoxidil&rank=1|archivedate=2017-01-18|df=}} 21. ^1 2 3 4 {{cite book|last=Conrad|first=Peter|date=2008|title=The Medicalization of Society: On the Transformation of Human Conditions into Treatable Disorders|chapter=Extension|chapter-url=https://books.google.com/books?id=cAE5hlP5YkAC&pg=PA37&dq#v=onepage&q&f=false|location=|publisher=JHU Press|page=37|isbn=978-0801892349|accessdate=2015-05-11}} (Google Books) 22. ^1 {{Cite news|url=https://www.nytimes.com/2014/09/20/business/guinter-kahn-inventor-of-baldness-remedy-dies-at-80.html |title=Guinter Kahn, Inventor of Baldness Remedy, Dies at 80 |author=Douglas Martin |publisher=The New York Times |date=2014-09-19 |archive-url=https://www.webcitation.org/6YRNnA645?url=http://www.nytimes.com/2014/09/20/business/guinter-kahn-inventor-of-baldness-remedy-dies-at-80.html?_r=1 |archive-date=2015-05-11 |accessdate=2015-05-11 |deadurl=yes |df= |newspaper=The New York Times }} 23. ^{{cite journal|last1=Gilmore|first1=Edward|last2=Weil|first2=John|last3=Chidsey|first3=Charles|title=Treatment of Essential Hypertension with a New Vasodilator in Combination with Beta-Adrenergic Blockade|journal=New England Journal of Medicine|date=5 March 1970|volume=282|issue=10|pages=521–527|doi=10.1056/NEJM197003052821001|pmid=4391708}} 24. ^{{cite journal|last1=Gottlieb |first1=Thomas |last2=Katz |first2=Fred |last3=Chidsey |first3=Charles |date=March 1972 |title=Combined Therapy with Vasodilator Drugs and Beta Adrenergic Blockade |language= |journal=Circulation |volume=45 |issue=3 |doi=10.1161/01.CIR.45.3.571 |pages=571–582 }} 25. ^1 {{cite journal |url=https://firstclinical.com/journal/2006/0603_Patents.pdf |title=When Patents Became Interesting in Clinical Research |author=Norman M. Goldfarb |journal=The Journal of Clinical Research Best Practices |volume=2 |issue=3 |date=March 2006 |archive-url=https://www.webcitation.org/6YRZmJ7Ak?url=https://firstclinical.com/journal/2006/0603_Patents.pdf |archive-date=2015-05-11 |accessdate=2015-05-11 |deadurl=yes |df= }} 26. ^1 2 3 {{cite web|url=https://news.google.com/newspapers?nid=1957&dat=19960513&id=dT5GAAAAIBAJ&sjid=QukMAAAAIBAJ&pg=1622,3318023&hl=en|title=Hair-rasing tale: no fame for men who discovered Rogaine|website=|author=Will Lester|publisher=The Daily Gazette|date=May 13, 1996|accessdate=2015-05-11}} 27. ^1 {{cite book|last=Kuntzman|first=Gersh|date=2001|title=Hair!: Mankind's Historic Quest to End Baldness|chapter=|url=https://books.google.com/books?id=omYBD2Ncn4YC&pg=PT172&lpg=PT172&dq=#v=onepage&q&f=false|location=|publisher=Random House Publishing Group|page=172|isbn=978-0679647096|accessdate=2015-05-11}} (Google Books) 28. ^{{cite book|last=Pray|first=Stephen W.|date=2006|title=Nonprescription Product Therapeutics|chapter=|url=https://books.google.com/books?id=XU1sMK1djVAC&pg=PA663&dq#v=onepage&q&f=false|location=|publisher=Lippincott Williams & Wilkins|page=663|isbn=978-0781734981|accessdate=2015-05-11}} (Google Books) 29. ^1 {{cite journal|last1=Varothai|first1=S|last2=Bergfeld|first2=WF|title=Androgenetic alopecia: an evidence-based treatment update.|journal=American Journal of Clinical Dermatology|date=July 2014|volume=15|issue=3|pages=217–30|pmid=24848508|doi=10.1007/s40257-014-0077-5}} 30. ^1 Drugs.com [https://www.drugs.com/international/minoxidil.html International brand names for minoxidil] {{webarchive|url=https://web.archive.org/web/20170808074434/https://www.drugs.com/international/minoxidil.html |date=2017-08-08 }} Page accessed June 26, 2017 External links
{{Nonsympatholytic vasodilatory antihypertensives}}{{Other dermatological preparations}}{{Ion channel modulators}} 6 : Amine oxides|Hair loss medications|Piperidines|Pyrimidines|Vasodilators|Potassium channel openers |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。